BioSpace News Archive

Bristol Myers Squibb announced the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® plus Yervoy® compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Obsidian Therapeutics, Inc. today announced the appointment of William Pao, M.D., Ph.D., to the company’s Board of Directors as an independent member.

Mission Bio today announced the launch of the Tapestri® Single-cell Multiple Myeloma Multiomics Solution.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis.

Artelo Biosciences, Inc. today announced that Professor Saoirse O’Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society.

XORTX Therapeutics Inc. is pleased to announce its participation in the BIO International Convention 2024, being held June 3rd through 6th , 2024.

Bridge to Life Ltd, a leading provider of organ preservation solutions, has announced the latest findings from the Bridge to HOPE clinical trial, utilizing the VitaSmart Machine Perfusion System.

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) will convene a Medical Device Advisory Committee for a panel meeting (the “Advisory Panel”) to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® to help the FDA make a sound decision.

AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.